Stay updated on Acalabrutinib in Ovarian Cancer Clinical Trial
Sign up to get notified when there's something new on the Acalabrutinib in Ovarian Cancer Clinical Trial page.

Latest updates to the Acalabrutinib in Ovarian Cancer Clinical Trial page
- Check4 days agoChange DetectedThe page underwent a visual/UI refresh with a new header and updated formatting; no core content such as study title, NCT number, eligibility criteria, or outcomes changed. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.4%

- Check11 days agoNo Change Detected
- Check32 days agoChange Detected- Added a government funding notice and operating status guidance, plus a pointer to cc.nih.gov; - Bumped version from v3.1.0 to v3.2.0.SummaryDifference6%

- Check40 days agoChange DetectedRebranding: replace Genetic and Rare Diseases Information Center with MedlinePlus Genetics and update to Revision v3.1.0; related topics added. Old center name and resources removed (v3.0.2).SummaryDifference1%

- Check47 days agoChange DetectedRemoved a MedlinePlus Genetics topic on Ovarian cancer from the page.SummaryDifference0.4%

- Check54 days agoChange DetectedVersion bumped from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed. No substantive changes to core content, pricing, or time-sensitive information.SummaryDifference0.3%

- Check61 days agoChange DetectedThe web page has been updated from version 3.0.0 to version 3.0.1, indicating a revision in the content. There are no significant changes to core content, names, pricing, or availability.SummaryDifference0.3%

Stay in the know with updates to Acalabrutinib in Ovarian Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Acalabrutinib in Ovarian Cancer Clinical Trial page.